ERNA.US Ernexa Therapeutics Inc.

Healthcare Biotechnology USA Stocks
1.68 USD
Close of Nov 14, 2026
1.67 38.02
Market cap
USD 2.84M
P/E
-
P/B
0.65x
ROE
-381.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ERNA.US undervalued?

Graham number

The Graham number of Ernexa Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ernexa Therapeutics Inc. fundamental analysis

No fundamental analysis for Ernexa Therapeutics Inc. yet.

Ernexa Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor B…

Full company profile